Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation.

"Declarations Ethics approvalAll procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Data Management Committee of the Japan Society for Transplantation and Cellular Therapy and the ethics committee of Kobe City Hospital Organization Kobe City Medical Center General Hospital (approval number: zn220316). Consent to participateWritten informed consent was obtained from each patient at each institution before Transplant Registry Unified Management Program 2 registration. Consent for publicationNot applicable. Competing interestsSK has received honoraria from Otsuka Pharmaceutical Co., Ltd. The other authors have no relevant financial or nonfinancial interests to disclose. Competing interests SK has received honoraria from Otsuka Pharmaceutical Co., Ltd. The other authors have no relevant financial or nonfinancial interests to disclose."